• Radiation Therapy
      • Treatment Delivery
        • Elekta Unity Elekta Unity
        • Elekta Versa HD® Elekta Versa HD®
        • Elekta Harmony Elekta Harmony
        • Elekta Infinity Elekta Infinity
      • Quality Assurance
        • Machine QA
        • Patient QA
    • Stereotactic Radiosurgery
      • Delivery
        • Elekta Esprit Elekta Esprit
        • Versa HD Versa HD
      • Treatment Planning
        • Leksell GammaPlan
    • Oncology Software
      • Elekta ONE
        • Oncology care
        • Smart Workflows
        • Treatment Applications
        • Real-world outcomes
        • Subscribe to Better
        • Elekta Axis Cloud
        • Interoperability
        • Professional Services
    • Brachytherapy
      • Delivery
        • Elekta Studio Elekta Studio
        • ImagingRing ImagingRing
        • Oncentra Brachy Oncentra Brachy
        • Venezia Venezia
        • Flexitron Flexitron
        • Geneva Geneva
        • Xoft Xoft
      • Body Sites
        • Head and Neck
        • Bronchus and Oesophagus
        • Breast
        • Skin
        • Prostate
        • Brachytherapy for rectal cancer
        • Bladder
        • Cervix
    • Neurosurgery
      • Delivery
        • Leksell Vantage Stereotactic System Leksell Vantage Stereotactic System
    • Veterinary Radiation Therapy
    • Life Sciences
      • Elekta Kaiku
    • Elekta Care
    • Elekta Care Support Services
    • Elekta Care 360
    • Elekta Care Learning
    • Elekta Care Community
    • Elekta Partner Community
    • MR-Linac Treatment
    • Brachytherapy Treatment
    • Gamma Knife Treatment
    • Radiation Therapy Treatment
    • Treatment Centers
    • Company
    • Partnering with Elekta
    • About us
      • About us
        • Board of Directors
        • Code of Conduct
        • Corporate Citizenship
        • Executive Committee
        • Integrity Line
        • Programs
        • Risk management
        • Story
    • Sustainability
    • Corporate Governance
      • Corporate Governance
        • Shareholders’ meetings
          • Board of Directors
            • Executive Committee
              • Auditors
              • Reports
          • Investors
            • Investors
              • Investment case
                • Outlook
                • Market and Trends
                  • The share
                    • Financials
                      • Funding
                        • Reports & presentations
                        • Press releases
                        • IR calendar
                        • IR contacts
                    • Newsroom
                      • Newsroom
                        • Press Releases
                        • FOCUS Magazine
                        • Events
                        • Image bank
                    • Careers at Elekta
                      • Jobs
                    • Reimbursement Support & Policy
                  ENSV
                  Login
                  • Products
                    • Radiation Therapy
                      • Treatment Delivery
                        • Elekta Unity
                        • Elekta Versa HD®
                        • Elekta Harmony
                        • Elekta Infinity
                      • Quality Assurance
                        • Machine QA
                        • Patient QA
                    • Stereotactic Radiosurgery
                      • Delivery
                        • Elekta Esprit
                      • Treatment Planning
                        • Leksell GammaPlan
                      • Versa HD
                    • Oncology Software
                      • Elekta ONE
                        • Oncology care
                        • Smart Workflows
                        • Treatment Applications
                        • Real-world outcomes
                        • Subscribe to Better
                        • Elekta Axis Cloud
                        • Interoperability
                        • Professional Services
                    • Brachytherapy
                      • Elekta Studio
                      • ImagingRing
                      • Venezia
                      • Flexitron
                      • Geneva
                      • Head and Neck
                      • Bronchus and Oesophagus
                      • Xoft
                      • Breast
                      • Skin
                      • Prostate
                      • Brachytherapy for rectal cancer
                      • Bladder
                      • Cervix
                      • Oncentra Brachy
                    • Neurosurgery
                      • Leksell Vantage Stereotactic System
                    • Veterinary Radiation Therapy
                    • Life Sciences
                      • Elekta Kaiku
                  • Services
                    • Elekta Care
                    • Elekta Care Support Services
                    • Elekta Care 360
                    • Elekta Care Learning
                    • Elekta Care Community
                    • Elekta Partner Community
                  • Patients
                    • MR-Linac Treatment
                    • Brachytherapy Treatment
                    • Gamma Knife Treatment
                    • Radiation Therapy Treatment
                    • Treatment Centers
                  • Company
                    • Partnering with Elekta
                    • About us
                      • Board of Directors
                      • Code of Conduct
                      • Corporate Citizenship
                      • Executive Committee
                      • Integrity Line
                      • Programs
                      • Risk management
                      • Story
                    • Sustainability
                    • Corporate Governance
                      • Shareholders’ meetings
                        • Board of Directors
                          • Executive Committee
                            • Auditors
                            • Reports
                          • Investors
                            • Investment case
                              • Outlook
                              • Market and Trends
                                • The share
                                  • Financials
                                    • Funding
                                      • Reports & presentations
                                      • Press releases
                                      • IR calendar
                                      • IR contacts
                                    • Newsroom
                                      • Press Releases
                                      • FOCUS Magazine
                                      • Events
                                      • Image bank
                                    • Careers at Elekta
                                      • Jobs
                                    • Reimbursement Support & Policy
                                  • Contact
                                  • Medical Affairs
                                  • Regulatory Affairs
                                  • Suppliers
                                    • About Elekta Procurement
                                    • Sustainable Sourcing
                                    • Performance Management
                                      • Production Part Approval Process
                                      • Supplier Escalation Form
                                      • Non Conformance Management
                                      • Supplier Performance Management
                                      • Obsolescence Management
                                    • Compliance Management
                                    • Invoicing Process
                                    • Elekta T&C
                                    • Documents & Training
                                    • Our Global Presence

                                  Year-end report, May–April 2023/24

                                  June 05, 2024

                                  A year of profitable growth

                                  In our fourth quarter, we faced challenging market conditions impacting our results negatively. We concluded a year of profitable growth resulting in an expanded EBIT margin of 150 basis point and we delivered a book-to-bill ratio of 1.09 for the full year. At the recent ESTRO exhibition, we successfully launched a new market leading CT-adaptive linac, Elekta Evo, completing our comprehensive product offering.

                                  Gustaf Salford
                                  President and CEO

                                  Fourth quarter

                                  • Gross order intake increased by 1 percent to SEK 6,436 M (6,359), corresponding to a 1 percent decrease in constant exchange rates
                                  • Net sales decreased by 2 percent to SEK 5,023 M (5,125), corresponding to a 2 percent decrease in constant exchange rates
                                  • Adjusted gross margin amounted to 36.6 percent (37.8)
                                  • Adjusted operating income (Adjusted EBIT) amounted to SEK 651 M (832), corresponding to an adjusted EBIT margin of 13.0 percent (16.2)
                                  • Earnings per share was SEK 1.08 (1.43) before dilution and SEK 1.08 (1.43) after dilution
                                  • Adjusted earnings per share was SEK 1.15 (1.53) before dilution and SEK 1.15 (1.53) after dilution
                                  • Cash flow after continuous investments amounted to SEK 872 M (1,574)

                                  Full year

                                  • Gross order intake decreased by 2 percent to SEK 19,697 M (20,143), corresponding to a 5 percent decrease in constant exchange rates
                                  • Net sales increased by 7 percent to SEK 18,119 M (16,869), corresponding to a 5 percent increase in constant exchange rates
                                  • Adjusted gross margin amounted to 37.5 percent (38.1)
                                  • Adjusted operating income (Adjusted EBIT) amounted to SEK 2,145 M (1,743), corresponding to an adjusted EBIT margin of 11.8 percent (10.3)
                                  • Earnings per share was SEK 3.41 (2.47) before dilution and SEK 3.41 (2.47) after dilution
                                  • Adjusted earnings per share was SEK 3.62 (3.11) before dilution and SEK 3.62 (3.10) after dilution
                                  • Cash flow after continuous investments amounted to SEK 815 M (400)
                                  • The Board of Directors proposes a dividend of SEK 2.40 (2.40) per share (paid in two installments)
                                  Group summaryQ4Full year
                                  SEK M2023/242022/23Δ2023/242022/23Δ
                                  Gross order intake6,4366,359-1%119,69720,143-5%1
                                  Net sales5,0235,125-2%118,11916,8695%1
                                  Adjusted gross margin 236.6%37.8%-1,2 ppts 37.5%38.1%-0,5 ppts 
                                  Adjusted EBITDA 39561,092-12%3,2872,80617%
                                  Adjusted EBITDA-margin 319,0%21,3%-2,3 ppts18,1%16,6%1,5 p.e.
                                  Adjusted EBIT 4651832-22%2,1451,74323%
                                  Adjusted EBIT margin 413,0%16,2%-3,3 ppts11,8%10,3%1,5 ppts
                                  Gross margin36.4%37.7%-1,3 ppts37.4%37.6%-0,2 ppts
                                  EBITDA9301,069-13%3,1892,59623%
                                  EBITDA-margin18,5%20,9%-2,4 ppts17,6%15,4%2,2 p.e.
                                  EBIT617784-21%2,0391,43143%
                                  EBIT margin12,3%15,3%-3 ppts11,3%8,5%2,8 ppts
                                  Cash flow after continuous investments8721,574-702815400415
                                  Adjusted earnings per share before/after dilution, SEK 51.15 / 1.151.53 / 1.53-24%3.62 / 3.623.11 / 3.1017%
                                  Earnings per share before/after dilution, SEK 1.08 / 1.081.43 / 1.43-24%3.41 / 3.412.47 / 2.4738%

                                  1 Compared to last fiscal year based on constant exchange rates.
                                  2 Adjusted gross margin = Gross margin excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 27.
                                  3 Adjusted EBITDA = EBITDA excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 28.
                                  4 Adjusted EBIT = Operating income (EBIT) excluding items affecting comparability, see page 28.
                                  5 Adjusted earnings per share = Net income attributable to Parent Company shareholders, excluding items affecting comparability, in relation to the weighted average number of shares (excluding treasury shares), see page 29.

                                  # # #
                                   
                                  For further information, please contact:
                                  Tobias Hägglöv, CFO
                                  Tel: +46 76 107 4799, e-mail: [email protected]  
                                  Time zone: CET: Central European Time

                                  Peter Nyquist, Head of Investor Relations
                                  Tel: +46 70 575 29 06, e-mail: [email protected]
                                  Time zone: CET (Central European Time)

                                  About Elekta
                                  As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on “X”, formerly known as Twitter.

                                  This information is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-06-05 07:30 CEST.

                                  Attachments


                                  Elekta Q4 23 24 English Report

                                  Downloads

                                  • Elekta Q4 23 24 English Report
                                  • Products
                                    • Radiation Therapy
                                    • Stereotactic Radiosurgery
                                    • Oncology Software
                                    • Brachytherapy
                                    • Neurosurgery
                                    • Veterinary Radiation Therapy
                                    • Life Sciences
                                  • Services
                                    • Elekta Care
                                    • Elekta Care Support Services
                                    • Elekta Care 360
                                    • Elekta Care Learning
                                    • Elekta Care Community
                                    • Elekta Partner Community
                                  • Patients
                                    • MR-Linac Treatment
                                    • Brachytherapy Treatment
                                    • Gamma Knife Treatment
                                    • Radiation Therapy Treatment
                                    • Treatment Centers
                                  • Company
                                    • Partnering with Elekta
                                    • About us
                                    • Sustainability
                                    • Corporate Governance
                                    • Investors
                                    • Newsroom
                                    • Careers at Elekta
                                    • Digital Product Security
                                    • Offices
                                    • Regional pages
                                  • ©2025 Elekta
                                  • Legal notices
                                  • Privacy policy
                                  • Cookies
                                  • Subscription center

                                  Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.

                                  © 2025 Elekta

                                  • Legal notices
                                  • Privacy policy
                                  • Cookies
                                  • Subscription center

                                  Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.